Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers
- PMID: 26181175
- DOI: 10.1001/jamaoncol.2015.0658
Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers
Abstract
Importance: Women who carry a germline mutation in either the BRCA1 or BRCA2 gene face a lifetime risk of breast cancer of up to 70%, and once they receive a diagnosis of breast cancer, they face high risks of both second primary breast and ovarian cancers. Preventive bilateral salpingo-oophorectomy is recommended to women with a BRCA mutation at age 35 years or thereafter to prevent breast and ovarian cancer, but it is unclear whether oophorectomy has an impact on survival in women with BRCA-associated breast cancer.
Objective: To estimate the impact of oophorectomy on survival in women with breast cancer with a BRCA1 or BRCA2 mutation.
Design, setting, and participants: Retrospective analysis of patients selected by pedigree review of families who received counseling at 1 of 12 participating clinical genetics centers. Patients were 676 women with stage I or II breast cancer and a BRCA1 or BRCA2 mutation who were observed for up to 20 years after receiving a diagnosis between 1975 and 2008. Survival experience was compared for women who did and who did not undergo oophorectomy.
Main outcomes and measures: In all analyses, the primary end point was death due to breast cancer.
Results: Of the 676 women, 345 underwent oophorectomy after the diagnosis of breast cancer and 331 retained both ovaries. The 20-year survival for the entire patient cohort was 77.4%. The adjusted hazard ratio for death attributed to breast cancer in women who underwent oophorectomy was 0.38 (95% CI, 0.19-0.77; P = .007) for BRCA1 carriers and 0.57 (95% CI, 0.23-1.43; P = .23) for BRCA2 carriers. The hazard ratio for breast cancer-specific mortality was 0.76 (95% CI, 0.32-1.78; P = .53) for women with estrogen receptor-positive breast cancer and 0.07 (95% CI, 0.01-0.51; P = .009) for women with estrogen receptor-negative breast cancer.
Conclusions and relevance: Oophorectomy is associated with a decrease in mortality in women with breast cancer and a BRCA1 mutation. Women with estrogen receptor-negative breast cancer and a BRCA1 mutation should undergo oophorectomy shortly after diagnosis.
Comment in
-
Adjuvant Oophorectomy in the Treatment of Early-Stage BRCA Mutation-Positive Breast Cancer.JAMA Oncol. 2015 Jun;1(3):313. doi: 10.1001/jamaoncol.2015.0708. JAMA Oncol. 2015. PMID: 26181176 No abstract available.
Similar articles
-
Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.Breast Cancer Res Treat. 2010 Dec;124(3):643-51. doi: 10.1007/s10549-010-0805-3. Epub 2010 Mar 4. Breast Cancer Res Treat. 2010. PMID: 20204502
-
Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.Gynecol Oncol. 2005 May;97(2):457-67. doi: 10.1016/j.ygyno.2005.01.039. Gynecol Oncol. 2005. PMID: 15863145
-
Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.JAMA. 2006 Jul 12;296(2):185-92. doi: 10.1001/jama.296.2.185. JAMA. 2006. PMID: 16835424
-
Management updates for women with a BRCA1 or BRCA2 mutation.Mol Diagn Ther. 2007;11(3):133-44. doi: 10.1007/BF03256234. Mol Diagn Ther. 2007. PMID: 17570734 Review.
-
Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.Gynecol Oncol. 2000 Sep;78(3 Pt 1):278-87. doi: 10.1006/gyno.2000.5861. Gynecol Oncol. 2000. PMID: 10985881 Review.
Cited by
-
BRCA genetic testing and counseling in breast cancer: how do we meet our patients' needs?NPJ Breast Cancer. 2024 Sep 5;10(1):77. doi: 10.1038/s41523-024-00686-8. NPJ Breast Cancer. 2024. PMID: 39237557 Free PMC article. Review.
-
Blood Iodine as a Potential Marker of the Risk of Cancer in BRCA1 Carriers.Nutrients. 2024 Jun 6;16(11):1788. doi: 10.3390/nu16111788. Nutrients. 2024. PMID: 38892720 Free PMC article.
-
Effects of Endocrine Interventions Targeting ERα or PR on Breast Cancer Risk in the General Population and Carriers of BRCA1/2 Pathogenic Variants.Int J Mol Sci. 2024 May 28;25(11):5894. doi: 10.3390/ijms25115894. Int J Mol Sci. 2024. PMID: 38892081 Free PMC article. Review.
-
Role of Breast Cancer Risk Estimation Models to Identify Women Eligible for Genetic Testing and Risk-Reducing Surgery.Biomedicines. 2024 Mar 22;12(4):714. doi: 10.3390/biomedicines12040714. Biomedicines. 2024. PMID: 38672070 Free PMC article. Review.
-
Advancing GCT Management: A Review of miR-371a-3p and Other miRNAs in Comparison to Traditional Serum Tumor Markers.Cancers (Basel). 2024 Mar 31;16(7):1379. doi: 10.3390/cancers16071379. Cancers (Basel). 2024. PMID: 38611057 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
